Target intelligence / Profile preview

Streptococcus thermophilus (S. thermophilus)

Target
S. thermophilus
Molecular classification
Bacterium, Lactic acid bacterium, Gram-positive bacterium, Viridans group streptococcus
01

Overview

Streptococcus thermophilus is a gram-positive, non-motile, non-spore-forming lactic acid bacterium belonging to the viridans group streptococci[1][2]. It is a facultative anaerobe commonly used as a starter culture in the production of yogurt and cheese due to its ability to rapidly ferment lactose into lactic acid and contribute desirable texture and flavor characteristics through exopolysaccharide synthesis[4]. S. thermophilus also produces beneficial molecules such as folic acid and formic acid that support other bacteria during fermentation processes. As a probiotic organism found naturally in the human gastrointestinal tract, it aids digestion by breaking down proteins like casein and helps people with lactose intolerance digest dairy products more easily[3]. Unlike some pathogenic relatives within the Streptococcus genus, S. thermophilus lacks virulence factors associated with disease; it does not adhere strongly to mucosal surfaces nor carry significant antibiotic resistance genes or mobile genetic elements linked to pathogenicity[4]. While widely regarded as safe for use in food products and supplements—even during pregnancy—there are rare reports of adverse events such as sepsis among highly vulnerable populations including immunocompromised individuals or premature infants[1][2][5]. There are no known drugs that specifically target this species nor established biomarkers for patient selection related to its use. S. thermophilus is not considered a therapeutic target like an enzyme or receptor but rather an industrially important microorganism used primarily for its probiotic properties and role in food biotechnology. ---

Other names
Streptococcus salivarius subsp. thermophilusS. thermophilus
02

Biological functions

Lactic acid production (fermentation)Protein and lipid digestion (including casein hydrolysis)Exopolysaccharide synthesisAntimicrobial activity (bacteriocin production)ImmunomodulationAcidification of milk in dairy fermentation
03

Disease associations

Infection (rare; generally considered non-pathogenic but can cause sepsis in immunocompromised individuals)Other (probiotic effects, gut health)
04

Safety considerations

Generally recognized as safe for most populationsRare risk of sepsis in immunocompromised or critically ill patients, premature infants, or those with central venous catheters or heart valve disease

Beyond the preview

Go deeper on Streptococcus thermophilus (S. thermophilus).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus thermophilus (S. thermophilus).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call